Even though the clinical relevance from the aforementioned cardiovascular possibility factor alterations by tirzepatide will probably be assessed in the planned cardiovascular consequence analyze SURPASS-CVOT ( "kind":"medical-trial","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-E